期刊文献+

头孢布烯序贯疗法及其研究进展 被引量:1

下载PDF
导出
摘要 序贯疗法(sequential therapy)也称转换疗法(switch therapy,transition therapy)、降级疗法(stepdown therapy),在抗感染治疗中尤以儿科应用最多。序贯疗法的提出,是由于目前临床面临如下严重的情况①医疗费用增加:儿科感染性疾病发生率较高,抗生素应用广泛,且静脉用药过多所致;②医疗资源浪费:〉20%的患儿在病情好转或稳定后,并不需要继续住院治疗,若继续静脉给药和住院,
作者 翁春梅
出处 《药物流行病学杂志》 CAS 2008年第2期80-83,共4页 Chinese Journal of Pharmacoepidemiology
  • 相关文献

参考文献17

二级参考文献71

  • 1游雪梅,钟丽,陈德风.头孢克肟转换治疗胆道感染的疗效及对护理工作的影响[J].白云医药,2002(1):5-5. 被引量:1
  • 2张忠顺,肖和平.乳酸左氧氟沙星序贯疗法治疗耐多药肺结核的临床研究[J].中国抗生素杂志,2001,26(2):131-133. 被引量:4
  • 3李家泰,侯杰,高磊,陈亦芳,贾玉霞,缪竞智,孙春华,张秀珍,刘德辉,周伟,李家宏,王汝龙,王曼丽.头孢泊肟酯治疗细菌性感染122例临床评价[J].中华内科杂志,1994,33(7):440-443. 被引量:12
  • 4李光辉,张婴元,吴卫红,吴培澄,汪复.氧氟沙星序贯疗法治疗细菌性感染[J].新药与临床,1996,15(5):280-282. 被引量:10
  • 5吴瑞萍 胡亚美.诸福棠实用儿科学(第6版)[M].北京:人民卫生出版社,1997.567,26,1326.
  • 6[8]Cunha BA.Intravenous to oral antibiotic switch therapy[J].Drugs of Today,2001,37(5):311.
  • 7[25]卢结文,黄焯波.抗生素序贯或全程静脉给药用于妇科术后预防感染的成本-效果分析[N].医药经济报,2003-05-02(4)
  • 8[28]Cunha BA.Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community acquired pneumonia [ J ].Am J Med,2001,111(5):412.
  • 9[29]Ramirez JA,Bordon J.Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae [ J].Arch Intern Med,2001,161(6):848.
  • 10[30]Castro-Guardiola A,Viejo-Rodriguez AL,Soler-Simon S,et al.Efficacy and safety of oral and early-swicth therapy for community-acquired pneumonia:a randomized controlled trial [ J ].Am J Med,2001,111(5):367.

共引文献99

同被引文献17

  • 1肖永红.抗菌药物的药代动力学/药效学概念及其临床意义[J].中华医学杂志,2004,84(22):1914-1915. 被引量:36
  • 2童夏生,王恩智,冯利平.口服头孢克肟治疗35例儿童泌尿系统感染的临床分析[J].中国抗生素杂志,2005,30(5):311-313. 被引量:5
  • 3王珍.头孢克肟颗粒治疗儿童社区获得性细菌性肺炎疗效观察[J].中国医药导报,2007,4(06Z):44-45. 被引量:8
  • 4de la Pe(n)a A,Gr(a)be A,Rand KH,et al.PK-PD modelling of the effect of cefaclor on four different bacterial strains[J].Int J Antimicrob Agents,2004,23(3):218-225.
  • 5Harrison CJ,Woods C,Stout G,et al.Epub 2009 Jan 27.Susceptibilities of Haemophilus influenzae,Streptococcus pneumoniae,including serotype 19A,and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics[J].J Antimicrob Chemother,2009,63(3):511-519.
  • 6Owens RC Jr,Ambrose PG.Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era[J].Diagn Microbiol Infect Dis,2007,57(S3):77-83.
  • 7Yanagawa A,Shimada J,Mori N,et al.Effects of gastrointestinal stimulant and suppressant pretreatment on the pharmacokinetics of AS-924,a novel ester-type cephem antibiotic[J].Int J Antimicrob Agents,2001,18(5):483-487.
  • 8Edwalr B,Slettevold L,Thurmann-Nielseii E,et al.Pharmacokinetics of oral cefcanel daloxate hydrochloridein healthy volunteers and patients with various degrees of impaired renal function[J].J Antimicrob Chemother,1994,33(2):281-288.
  • 9Griffith DC,Harford L,Williams R,et al.In vivo antibacterial activity of RWJ-54428,a new cephalosporin with activity against gram-positive bacteria[J].Antimicrob Agents Chemother,2003,47(1):43-47.
  • 10Hecker SJ,Calkim T,Price ME,et al.Prodrugs of cephalosporin RWJ-333441(MC-04,546) with improved aqueous solubility[J].Antimicrob Agents Chemother,2003,47(6):2043-2046.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部